Deals Of The Week: Selecta/JDRF, Lilly/Synthes, Merck/Roche
Executive Summary
Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.
You may also be interested in...
Selecta To Perform Preclinical Malaria Vaccine Work For SAIC
Biotech will combine its SVP platform technology with a SAIC-developed antigen to try to find the key to treating malaria.
The Value Lab: Moving Value-Based Health Care From Theory To Practice
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.